AntidiabeticsAntidiabeticA class of drugs used to lower blood glucose, acting by different mechanisms (e.g. insulin sensitisation, renal glucose excretion, incretin effect).
Metformin vs Empagliflozin
The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.
 Metformin |  Empagliflozin | |
|---|---|---|
| What it is | First-line oral therapy for type 2 diabetes worldwide. WHO Essential Medicines, ADA and EASD guideline anchor since 1957. | SGLT2 inhibitor (Jardiance), Boehringer Ingelheim/Eli Lilly. Cardio-reno-protective drug for T2DM + HFrEF/HFpEF + CKD. |
| ATC codeATC codeThe WHO Anatomical Therapeutic Chemical code that classifies drugs by organ system and mechanism. | A10BA02 | A10BK03 |
| Prescription | Prescription only (Rx) | Prescription only (Rx) |
| MechanismMechanism of actionThe molecular pathway by which a compound acts in the body (e.g. which receptor or enzyme it binds). | AMPK activator, hepatic gluconeogenesis inhibitor | SGLT2 (sodium-glucose cotransporter 2) inhibitor, proximal renal tubule |
| Half-lifeHalf-lifeThe time for the compound’s plasma concentration to fall by half; indicates how fast it clears and how often it is dosed. | 4-9 h (plasma), 17 h (erythrocyte) | ~12.4 h (once-daily dosing) |
| OnsetOnsetThe time from dosing until a measurable effect appears. | 1-3 h (single dose), 4-7 days (steady-state HbA1c) | Glucosuria within first dose; HbA1c and blood pressure changes over several weeks |
| Full entry | Open → | Open → |
What it is
MetforminFirst-line oral therapy for type 2 diabetes worldwide. WHO Essential Medicines, ADA and EASD guideline anchor since 1957.
EmpagliflozinSGLT2 inhibitor (Jardiance), Boehringer Ingelheim/Eli Lilly. Cardio-reno-protective drug for T2DM + HFrEF/HFpEF + CKD.
ATC codeATC codeThe WHO Anatomical Therapeutic Chemical code that classifies drugs by organ system and mechanism.
MetforminA10BA02
EmpagliflozinA10BK03
Prescription
MetforminPrescription only (Rx)
EmpagliflozinPrescription only (Rx)
MechanismMechanism of actionThe molecular pathway by which a compound acts in the body (e.g. which receptor or enzyme it binds).
MetforminAMPK activator, hepatic gluconeogenesis inhibitor
EmpagliflozinSGLT2 (sodium-glucose cotransporter 2) inhibitor, proximal renal tubule
Half-lifeHalf-lifeThe time for the compound’s plasma concentration to fall by half; indicates how fast it clears and how often it is dosed.
Metformin4-9 h (plasma), 17 h (erythrocyte)
Empagliflozin~12.4 h (once-daily dosing)
OnsetOnsetThe time from dosing until a measurable effect appears.
Metformin1-3 h (single dose), 4-7 days (steady-state HbA1c)
EmpagliflozinGlucosuria within first dose; HbA1c and blood pressure changes over several weeks
Full entry